Additionally, cerebrospinal fluid biomarkers, such as elevated levels of phosphorylated Tau and decreased β-amyloid 42, have proven useful in differentiating PSP from Alzheimer’s disease [58]. This evidence concerns the gene MAPT and Alzheimer disease.